ID   VXG3
AC   CVCL_J128
DR   cancercelllines; CVCL_J128
DR   Wikidata; Q54993440
RX   Patent=US5976860;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11865.
CC   Population: Caucasian.
CC   Characteristics: Infected with Ehrlichia.
CC   Sequence variation: Gene deletion; HGNC; HGNC:11998; TP53; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C7961; Adult acute myeloid leukemia with maturation
DI   ORDO; Orphanet_98834; Acute myeloblastic leukemia with maturation
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0002 ! HL-60
SX   Female
AG   36Y
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 14-08-25; Version: 22
//
RX   Patent=US5976860;
RA   Coughlin, Richard T.
RA   Gingrich-Baker, Cindy
RT   "Cell lines infected with granulocytic Ehrlichia, vaccines,
RT   diagnostics and methods.";
RL   Patent number US5976860, 02-Nov-1999.
//